Guggenheim analyst Michael Schmidt downgraded Arvinas (ARVN) to Neutral from Buy and removed his prior price target of $66 on the shares following company disclosures this week that he sees raising the development and timeline risks for lead program ARV-471. Arvinas disclosed that its combination studies of ARV-471 with Pfizer’s (PFE) palbociclib require additional dosing work and regulatory feedback before initiating Phase III development in first-line mBC and that initiation of the planned first-line mBC trial has been pushed back by about 6-12 months, noted Schmidt, who sees this extending the development gap versus potential competitor SERD programs from Roche (RHHBY), Eli Lilly (LLY) and AstraZeneca (AZN).
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ARVN:
- Arvinas downgraded to Neutral from Buy at Guggenheim
- Arvinas price target lowered to $27 from $43 at Wedbush
- Arvinas price target lowered to $95 from $102 at Oppenheimer
- Arvinas to Present at 41st Annual J.P. Morgan Healthcare Conference
- Wells Fargo downgrades Arvinas to Equal Weight, lowers price target to $49